이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Shandong Wohua Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 6/6

Shandong Wohua Pharmaceutical 의 총 주주 지분은 CN¥842.2M 이고 총 부채는 CN¥0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 CN¥1.2B 및 CN¥319.5M 입니다. Shandong Wohua Pharmaceutical 의 EBIT는 CN¥30.2M 이며 이자보상배율은 -5.4 입니다. CN¥456.7M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

CN¥0

부채

이자 보상 비율	-5.4x
현금	CN¥456.69m
주식	CN¥842.24m
총 부채	CN¥319.51m
총 자산	CN¥1.16b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Apr 05

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Mar 08

재무 상태 분석

단기부채: 002107 의 단기 자산 ( CN¥698.3M )이 단기 부채( CN¥297.2M ).

장기 부채: 002107 의 단기 자산( CN¥698.3M )이 장기 부채( CN¥22.3M ).

부채 대 자본 내역 및 분석

부채 수준: 002107 부채가 없습니다.

부채 감소: 002107 5년 전에 부채가 없었습니다.

부채 범위: 002107 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 002107 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Shandong Wohua Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Now 20% undervalued after recent price drop

Now 24% undervalued after recent price drop

Now 19% undervalued after recent price drop

Now 21% undervalued after recent price drop

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 03, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 21%

New major risk - Dividend sustainability

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in FY 2022)

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Now 22% overvalued

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Now 23% overvalued

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.042 (vs CN¥0.04 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.019 (vs CN¥0.05 in 2Q 2022)

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Jul 29, 2023

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.28 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 2Q 2021)

Now 21% undervalued after recent price drop

High number of new directors

First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 1Q 2021)

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.081 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.075 in 1Q 2020)

New 90-day low: CN¥7.39

New 90-day low: CN¥7.55

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021

Full year 2020 earnings released: EPS CN¥0.31

Full year 2020 earnings released: EPS CN¥0.31

Investor sentiment improved over the past week

New 90-day low: CN¥8.10

New 90-day low: CN¥8.90

Third quarter earnings released

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 16, 2020

New 90-day low: CN¥9.24

New 90-day low - CN¥10.07

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 16, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기